Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 9, 2021

NIH launches last trial of anticoagulant treatments for Covid-19

The US National Institutes of Health (NIH) has initiated the last of three Phase III clinical trials of blood thinners (anticoagulant) to prevent life-threatening blood clots in adults with Covid-19.

The US National Institutes of Health (NIH) has initiated the last of three Phase III clinical trials of blood thinners (anticoagulant) to prevent life-threatening blood clots in adults with Covid-19.

The first patient for the trial was enrolled on 15 February. It will analyse the use of Bristol Myers Squibb/Pfizer’s anticoagulant, Eliquis (apixaban 2.5mg) in patients discharged from the hospital following a diagnosis of moderate-to-severe Covid-19.

The third of the ACTIV-4 Antithrombotics master protocol for adaptive trials is ACTIV-4 Convalescent trial while two other trials, on hospitalised and non-hospitalised Covid-19 patients, respectively, are progressing.

This randomised and placebo-controlled trial will analyse whether patients develop any thrombotic complications, such as heart attack, stroke, blood clots in major veins and arteries, deep vein and pulmonary thrombosis, or death within 45 days of hospitalisation.

Supervised by the NIH unit National Heart, Lung, and Blood Institute (NHLBI), the trials are being carried out at over 100 sites worldwide.

Researchers have observed that during the early days of the Covid-19 pandemic, several patients who died of the disease had formed blood clots throughout their bodies, including the smallest blood vessels.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The ACTIV-4 trials will aid in providing answers to questions on the use of anticoagulants called antithrombotics for Covid-19 treatment.

Meanwhile, the IMIC Medical Research center has added novel agents to the ACTIV-2 clinical trial in Miami-Dade to analyse early Covid-19 treatments.

Monoclonal antibodies developed by Brii Biosciences, BRII-196, and BRII-198 target different parts of SARS-CoV-2.

The combination of these two agents could potentially enhance efficacy and lower the chances of virus developing resistance to the treatment.

Subjects in the Phase III trial will be given the combination agent and no placebo.

In addition, another available treatment is AstraZeneca’s monoclonal antibodies AZD7442 (IV) or (IM), a combination of two human monoclonal antibodies, or protease inhibitor Camostat for oral administration.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU